These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 33967024)

  • 1. Validation of cobas 4800 HPV assay in SurePath Papanicolaou specimens for cervical cancer screening.
    Guo M; Shlyakhova N; Khanna A; Tinnirello AA; Schmeler KM; Hwang J; Sturgis EM; Stewart J
    J Am Soc Cytopathol; 2021; 10(4):399-405. PubMed ID: 33967024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analytical performance of cervista HPV 16/18 in SurePath pap specimens.
    Guo M; Khanna A; Feng J; Patel S; Zhang W; Gong Y; Huo L; Staerkel G
    Diagn Cytopathol; 2015 Apr; 43(4):301-6. PubMed ID: 25352375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
    Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
    Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the Aptima and Cervista tests for detection of high-risk human papillomavirus in cervical cytology specimens.
    Nolte FS; Ribeiro-Nesbitt DG
    Am J Clin Pathol; 2014 Oct; 142(4):561-6. PubMed ID: 25239425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immediate histopathologic follow-up of cervista and aptima high-risk HPV assays in women with LSIL cytology.
    Zhang H; Varma KR; Han M; Matsko J; Zhao C
    Cancer Cytopathol; 2018 Aug; 126(8):525-532. PubMed ID: 29797678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A population-based observational study comparing Cervista and Hybrid Capture 2 methods: improved relative specificity of the Cervista assay by increasing its cut-off.
    Boehmer G; Wang L; Iftner A; Holz B; Haedicke J; von Wasielewski R; Martus P; Iftner T
    BMC Infect Dis; 2014 Dec; 14():674. PubMed ID: 25487281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical validation of the Cobas 4800 HPV assay using cervical samples in SurePath medium under the VALGENT4 framework.
    Ejegod DM; Hansen M; Christiansen IK; Pedersen H; Quint W; Xu L; Arbyn M; Bonde J
    J Clin Virol; 2020 Jul; 128():104336. PubMed ID: 32446166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and Analytical Performance of the BD Onclarity HPV Assay with SurePath Screening Samples from the Danish Cervical Screening Program Using the VALGENT Framework.
    Bonde JH; Pedersen H; Quint W; Xu L; Arbyn M; Ejegod DM
    J Clin Microbiol; 2020 Jan; 58(2):. PubMed ID: 31723012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An analysis of human papillomavirus testing and endocervical component on pap tests: A pilot study using the Roche Cobas(®) assay.
    Pierce KJ; Currens HS; Tafe LJ; Tsongalis GJ; Padmanabhan V
    Diagn Cytopathol; 2016 Apr; 44(4):280-2. PubMed ID: 26801205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evaluation of the effectiveness of BMRT-HPV for cervical cancer screening].
    Duan LF; Du H; Wang C; Huang X; Qu XF; Duan XZ; Liu Y; Shi B; Zhang W; Wei LH; Belinson L; Wu RF
    Zhonghua Fu Chan Ke Za Zhi; 2020 Oct; 55(10):708-715. PubMed ID: 33120484
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of a Newly Developed HPV Genotyping Assay (Mojin HPV Kit) with Cobas 4800 HPV Test for Detection of High-Risk HPV in Specimens Collected in SurePath Solution.
    Yang WW; Wang ZG; Chen GF; Shi JF; Chen J; Ma QH; Zhou J; Mao XD; Liu C; Yao XM
    Clin Lab; 2018 Mar; 64(3):387-391. PubMed ID: 29739098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of The Cervista HPV A9 group In Screening Patients for Cervical Cancer.
    Zhao J; Du H; Belinson JL; Qu X; Zhang W; Mei J; Yang B; Wang C; Zhang L; Wu R
    J Med Screen; 2016 Mar; 23(1):38-43. PubMed ID: 26466824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HPV detection rates and histopathologic follow-up of patients with HSIL cytology in a large academic women's hospital laboratory.
    Ashman D; Zhang H; Li J; Austin M; Wang T; Pradhan D; Zhao C
    J Am Soc Cytopathol; 2020; 9(6):550-555. PubMed ID: 32475726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical validation of the Cervista HPV HR and 16/18 genotyping tests for use in women with ASC-US cytology.
    Einstein MH; Martens MG; Garcia FA; Ferris DG; Mitchell AL; Day SP; Olson MC
    Gynecol Oncol; 2010 Aug; 118(2):116-22. PubMed ID: 20488510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The performance of human papillomavirus DNA detection with type 16/18 genotyping by hybrid capture in primary test of cervical cancer screening: a cross-sectional study in 10,669 Chinese women.
    Zhao X; Wu Q; Wang X; Fu Y; Zhang X; Tian X; Cheng B; Lu B; Yu X; Lan S; Lu W; Ma D; Cheng X; Xie X
    Clin Microbiol Infect; 2018 Dec; 24(12):1322-1327. PubMed ID: 29518562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitivity of high-risk HPV Hybrid Capture II (hrHPV HC2) test using SurePath(TM) specimens in the prediction of cervical high-grade squamous lesions.
    Zhou F; Pulinthanathu R; Elgert P; Cangiarella J; Simsir A
    Diagn Cytopathol; 2015 May; 43(5):381-7. PubMed ID: 25546355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experience of Combined Liquid Based Cervical Cytology and High-Risk HPV mRNA for Cervical Cancer Screening in Thammasat University Hospital.
    Muangto T; Chanthasenanont A; Lertvutivivat S; Nanthakomon T; Pongrojpaw D; Bhamarapravatana K; Suwannarurk K
    Asian Pac J Cancer Prev; 2016; 17(9):4409-4413. PubMed ID: 27797253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of prior cervical cytology and HR-HPV testing in women subsequently diagnosed with CIN1, CIN2/3, and invasive cervical cancer: a 4-year routine clinical experience after implementation of systematic training and quality control programs.
    Zhao D; Zhang L; Xie F; Peng D; Wei J; Jiang L; Zhang S; Qi D
    BMC Cancer; 2020 Aug; 20(1):810. PubMed ID: 32847541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison Study of BD Onclarity HPV With digene HC2 High-Risk HPV DNA Test and Roche Cobas 4800 HPV for Detecting High-Risk Human Papillomavirus in Japan.
    Nakamura M; Nakade K; Orisaka S; Iwadare J; Mizumoto Y; Fujiwara H
    Am J Clin Pathol; 2019 Feb; 151(3):263-269. PubMed ID: 30260388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of positive screening test results and agreement between cytology and human papillomavirus testing in primary cervical cancer screening in North-Western Romania.
    Şuteu O; Blaga ML; Nygård M; Leinonen MK; Nicula F; Păiş R; Coza D; Cadariu PA; Melnic A; Andreassen T; Hashim D; Weiderpass E
    Eur J Cancer Prev; 2020 Mar; 29(2):141-148. PubMed ID: 31033568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.